Optimized subunit vaccine protects against experimental leishmaniasis. - Wikidata - awgldk - TriplyDB

Optimized subunit vaccine protects against experimental leishmaniasis.

Optimized subunit vaccine protects against experimental leishmaniasis.

http://www.wikidata.org/entity/Q37439440

about

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant Possibilities and challenges for developing a successful vaccine for leishmaniasis Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity The Crystal Structures of the Tryparedoxin-Tryparedoxin Peroxidase Couple Unveil the Structural Determinants of Leishmania Detoxification Pathway Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran.Development of Vaccines against Visceral Leishmaniasis Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice The importance of adjuvant formulation in the development of a tuberculosis vaccine.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.The development and clinical evaluation of second-generation leishmaniasis vaccines.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses Adjuvants for Leishmania vaccines: from models to clinical application.Differential Immune Response against Recombinant Leishmania donovani Peroxidoxin 1 and Peroxidoxin 2 Proteins in BALB/c Mice.Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Current and novel approaches to vaccine development against tuberculosis.Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.Sand-fly saliva-leishmania-man: the trigger trio Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery.Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge.Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol.

P2860

Q21091066-5DEBE9B6-0D48-4353-9C78-AE93EE4E0B84 Q26749758-1D2B5E85-48A0-45ED-9D48-C69BCAFA16C7 Q27312070-95163C4C-86CC-4F33-831D-D4861404A861 Q27671738-E146F723-92EF-434C-AB26-06A1CC560EAD Q28476049-26B21A6C-B057-416F-A4F3-EB248779A997 Q28486287-715020E5-5E5C-438E-9B5F-0FC9AFD7AA59 Q28541600-7151E28E-2CF6-489F-B339-D3D3CB6F10F8 Q33579979-C9016243-43A7-470E-8382-A46660EB00CA Q33737949-F91E5517-2508-4D55-95D6-FD646E1D1FA6 Q34076804-BD987281-C4E6-4EA3-BFFD-A486119AEAA5 Q34235741-F89E4ED3-D018-40AB-BD4A-E7BABCD0E3A7 Q35029988-DE245FE7-8617-40BB-AB83-D47195A54DE5 Q35033838-6DC61179-D60B-4DC4-83BB-A07B31A2B761 Q35138682-713127DD-000E-4405-AE81-A2A546FD12CB Q35152067-2692A929-B7E7-44D1-BA01-A95A1814F343 Q35207606-7F25572C-C1B7-4206-B4EA-7D26ACB2A843 Q35634197-1D5552DC-B51F-46B9-8BF1-445B9860BFCB Q35783475-CA59E2E7-F437-4A04-BC76-58E7D3083537 Q35809113-5EA1F8B1-1EF9-403F-8AA0-0A0CAA600172 Q35986733-2D625D7E-4239-4778-B764-E9D046D392E0 Q35990046-DC8079C1-A0B8-4D78-8C4E-4AF2ED6C3157 Q36021357-7BCDCBCF-6CC1-4639-9411-4A25B0A51759 Q36035026-B94EE9DB-2DE1-426A-990F-ADC46EE89B51 Q36105743-B4C3A825-9F1F-4930-B971-72918C45EF00 Q36449189-29453AF2-7A53-4645-ADF5-F04AE0A86A63 Q36555077-473E37C0-6DC7-4CE3-9CF2-833B8DF86EEA Q36646698-0FD7751A-C9A5-4755-BBA7-1CDB31CB8249 Q36682576-A543F36C-0E4C-4C29-B129-1FD89E05E377 Q36957252-0F790800-1DC5-4D95-9D35-6066960BC761 Q37321931-CB5298BD-1F5A-45CC-B8F0-7D465B34ED21 Q37434214-D0C19F86-A0A0-4EE6-8CDF-A6926B1DF253 Q37965724-F8F8CFC4-4BEB-4652-B8E2-13F411AAD483 Q38124063-8A1AB20F-C101-4431-BC8E-BCA329050284 Q38284074-E11212D3-B34F-4E9E-BAA5-1CAD13414B04 Q38658902-D6A5976C-9816-4BFD-8959-1DB2864258C1 Q41146226-4828AB5C-FCE2-4820-BEBF-C4E9706042B5 Q42117985-59D50416-4552-4EA5-B90A-513D04C40C76 Q42244601-9F958E80-27AC-4770-A4E1-78670405341C Q42428380-A1A3FD3C-7A30-4CF5-A1DB-E61FD25654DE Q44080405-8758CD98-64A0-499E-9D72-9A580A5A5BFA

P2860

Optimized subunit vaccine protects against experimental leishmaniasis.

http://www.wikidata.org/entity/Q37439440

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimized subunit vaccine protects against experimental leishmaniasis.

@en

Optimized subunit vaccine protects against experimental leishmaniasis.

@nl

type

label

Optimized subunit vaccine protects against experimental leishmaniasis.

@en

Optimized subunit vaccine protects against experimental leishmaniasis.

@nl

prefLabel

Optimized subunit vaccine protects against experimental leishmaniasis.

@en

Optimized subunit vaccine protects against experimental leishmaniasis.

@nl

P1433

Q37439440-25374AAA-141C-4A2E-BFDE-F82AA39F02AE

P1476

Q37439440-460B0F5D-46FC-4D8A-9AB5-9948FA3E9827

P2093

Q37439440-508D9BC1-E531-4AA1-BE00-B0D43A4AB44B

Q37439440-7BD79DF0-5F3D-4997-9469-93E48D26B634

Q37439440-8ABC5A5D-57FE-4C84-BCF6-598D48CDA457

Q37439440-8CD52652-A935-46C3-86AB-DAA18125E72D

Q37439440-BC52E93A-E2CF-4FEA-8653-9F1D66AE0CBC

Q37439440-F703860B-7CAD-4344-8601-381A400BD547

P2860

Q37439440-09266059-06F0-47BC-9719-B64F200A19BF

Q37439440-0B392C78-9CEE-4073-AC34-C41E0B4FE1AB

Q37439440-0FB0FB81-FA7F-474B-ACD3-2C7EFF44D524

Q37439440-14783AA5-9D39-425E-A85F-737333F99329

Q37439440-18EA5021-108B-435F-833D-B68B5555EDF7

Q37439440-257AE7F7-4CCB-41D4-8050-85C87E0BEFBE

Q37439440-257F543F-89CB-49CB-9DA2-F30406064EB1

Q37439440-264EC336-F297-49FC-90B3-7AC127A67BB7

Q37439440-2693B2DA-5810-4927-9940-8D974E743531

Q37439440-2703E0D0-3EF2-4BAA-9D37-738DFBC154A6

P304

Q37439440-E966FACC-1915-4A7A-8423-BC841E2ED5C6

P31

Q37439440-0B107727-BA2D-484D-94BE-B259B606F999

P356

Q37439440-56BABD8B-F8F7-42B5-9404-01D3CAE313C6

P407

Q37439440-7EA5B4B8-B915-4FE1-A517-834F3ECDE6FC

P433

Q37439440-4CB3F343-C129-4883-80B7-BFD9845A73D2

P478

Q37439440-02C621D0-C506-41A0-9E19-BF7931020CCA

P50

Q37439440-312A3F7C-B117-404E-9690-97C330109DD4

Q37439440-33FBDE70-3C4C-4CF4-9873-AC95258C5B0A

Q37439440-DE1637E5-CC68-4031-9814-5A121F89A53A

P577

Q37439440-82869D5D-02DA-40AB-81C4-B0A3396D590F

P5875

Q37439440-E53AAC27-ED81-48F8-B2C1-07A754889D8F

P698

Q37439440-A68734CD-40D7-4A48-A641-B44577994D3A

P932

Q37439440-2217A049-6744-42CB-BCED-C8820215C545

P356

J.VACCINE.2009.09.066

P1433

P1476

Optimized subunit vaccine protects against experimental leishmaniasis.

@en

P2093

Ajay Bhatia

http://www.w3.org/2001/XMLSchema#string

Lauren Carter

http://www.w3.org/2001/XMLSchema#string

Randall F Howard

http://www.w3.org/2001/XMLSchema#string

Rhea N Coler

http://www.w3.org/2001/XMLSchema#string

Sylvie Bertholet

http://www.w3.org/2001/XMLSchema#string

Thomas S Vedvick

http://www.w3.org/2001/XMLSchema#string

P2860

Immunological concepts of vaccine adjuvant activity

Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells

Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Design and selection of vaccine adjuvants: animal models and human trials.

The immunology of susceptibility and resistance to Leishmania major in mice.

P304

7036-7045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.09.066

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26853087

http://www.w3.org/2001/XMLSchema#string

P698

19786136

http://www.w3.org/2001/XMLSchema#string

P932

2783536

http://www.w3.org/2001/XMLSchema#string